Literature DB >> 3035082

Immunogenicity of a hepatitis A virus vaccine.

B Flehmig, A Haage, M Pfisterer.   

Abstract

Hepatitis A virus (HAV) strain HAV/HFS/GBM was adapted to and grown in human diploid fibroblast cells. The HAV was concentrated by ammonium sulphate precipitation and high-speed centrifugation. The virus was inactivated by beta-propiolacton and purified by sedimentation through a 20% solution of sucrose and by CsCl gradient centrifugation. The immunogenicity of different preparations was tested in mice, guinea pigs, and goats. The immune response after vaccination was tested by determination of anti-HAV with RIA and of neutralizing antibodies with an appropriate test system. Results showed that anti-HAV titers of 1:1,000 and greater, as well as neutralizing antibody titers of 1:1,000 and greater, were found in sera of animals vaccinated with different preparations. It became evident that good anti-HAV titers persisted over a period of at least 1.5 years in goats and mice after immunization with a semipurified HAV vaccine, and titers up to 1:200 were present in mice 2 years after vaccination with a highly purified HAV vaccine.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3035082     DOI: 10.1002/jmv.1890220103

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  3 in total

Review 1.  Clinical development of a new inactivated hepatitis A vaccine.

Authors:  E Vidor; B Fritzell; S Plotkin
Journal:  Infection       Date:  1996 Nov-Dec       Impact factor: 3.553

2.  Evaluation of inactivated hepatitis A vaccine in Canadians 40 years of age or more.

Authors:  D W Scheifele; G J Bjornson
Journal:  CMAJ       Date:  1993-02-15       Impact factor: 8.262

3.  Study of the integrated immune response induced by an inactivated EV71 vaccine.

Authors:  Longding Liu; Ying Zhang; Jingjing Wang; Hongling Zhao; Li Jiang; Yanchun Che; Haijin Shi; Rongcheng Li; Zhaojun Mo; Teng Huang; Zhenglun Liang; Qunying Mao; Lichun Wang; Chenghong Dong; Yun Liao; Lei Guo; Erxia Yang; Jing Pu; Lei Yue; Zhenxin Zhou; Qihan Li
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.